Patents by Inventor Qingyi Li

Qingyi Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10457645
    Abstract: The present invention relates to method for the preparation of 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid, wherein it comprises the following steps: step 1, fluoroacetyl fluoride derivative shown in Formula I undergoes condensation with dimethylamino vinyl methyl ketone, as a result, 3-dimethylamino methylene-fluoro-2,4-pentanedione derivative shown in Formula II is formed; step 2, ring closing reaction takes place between said 3-dimethylamino methylene-fluoro-2,4-pentanedione shown in Formula II and methylhydrazine, in this way, 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is obtained; step 3, the said 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is oxidized in the presence of alkali, and then acidified, in this way, 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid shown in Formula IV is formed.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 29, 2019
    Assignee: CHANGZHOU KEYLAB BIOCHEMICAL CO., LTD.
    Inventors: Mingchun Wang, Qingyi Li
  • Patent number: 10428072
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 1, 2019
    Assignee: Eli Lilly and Company
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Publication number: 20190177729
    Abstract: Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4?-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4?-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5?-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4?-carbon of the sugar moiety or analog thereof.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 13, 2019
    Inventors: Weimin Wang, Qingyi Li, Naim Nazef
  • Publication number: 20190158960
    Abstract: The present invention provides a sound generation device and a preparation method of a metal plastic part. The sound generation device comprises a metal plastic part. The metal plastic part comprises a plastic part and a metal insert that is combined with the plastic part. An oxidation film that is obtained through metal nanocrystallization and a nanopore that is formed in a surface of the oxidation film and has a pore diameter of 20-1,000 nm are arranged on a surface of the metal insert. The nanopore is filled with a resin composition from which the plastic part is made. As the nanopore is filled with the resin composition from which the plastic part is made, the metal insert and the plastic part are in close fit with each other, which greatly enhances the gluing capability of the metal insert and prevents the metal insert and the plastic part which are formed through injection molding from being separated.
    Type: Application
    Filed: December 28, 2016
    Publication date: May 23, 2019
    Applicant: GOERTEK INC.
    Inventors: Qingyi ZHANG, Gang CHEN, Zhenjun LI, Shuangshuang FAN
  • Publication number: 20180273486
    Abstract: The present invention relates to method for the preparation of 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid, wherein it comprises the following steps: step 1, fluoroacetyl fluoride derivative shown in Formula I undergoes condensation with dimethylamino vinyl methyl ketone, as a result, 3-dimethylamino methylene-fluoro-2,4-pentanedione derivative shown in Formula II is formed; step 2, ring closing reaction takes place between said 3-dimethylamino methylene-fluoro-2,4-pentanedione shown in Formula II and methylhydrazine, in this way, 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is obtained; step 3, the said 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is oxidized in the presence of alkali, and then acidified, in this way, 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid shown in Formula IV is formed.
    Type: Application
    Filed: September 28, 2016
    Publication date: September 27, 2018
    Inventors: Mingchun WANG, Qingyi LI
  • Publication number: 20180230149
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: March 29, 2018
    Publication date: August 16, 2018
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Publication number: 20180117036
    Abstract: The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, active ingredient trimetazidine or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material, and 100:1 is the weight ratio of L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof and trimetazidine or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 3, 2018
    Inventors: Hebing XIE, Qingyi LI, Shuhua GU, Weihong LV
  • Publication number: 20170050966
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: April 23, 2015
    Publication date: February 23, 2017
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher Matthew Liu, Guohua Liang, Matthew F. Baevsky, Richard Alan Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Patent number: 9421181
    Abstract: The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: August 23, 2016
    Inventors: Hebing Xie, Qingyi Li, Shuhua Gu, Weihong Lv
  • Patent number: 9394308
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Blaise S. Lippa, Chester A. Metcalf, III, Andrew J. Jackson, Lauren M. Chapman
  • Publication number: 20160106741
    Abstract: The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, active ingredient trimetazidine or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material, and 100:1 is the weight ratio of L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof and trimetazidine or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2014
    Publication date: April 21, 2016
    Applicant: CHANGZHOU HI-TECH DISTRICT MULTIPLE DIMENSION INDUSTRY TECHNOLOGY INSTITUTE CO.
    Inventors: Hebing XIE, Qingyi LI, Shuhua GU, Weihong LV
  • Publication number: 20160081966
    Abstract: The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: March 24, 2016
    Inventors: Hebing XIE, Qingyi LI, Shuhua GU, Weihong LV
  • Patent number: 9096493
    Abstract: The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: August 4, 2015
    Assignee: Changzhou Multiple Dimension Institute of Industry Technology Co., Ltd.
    Inventors: Shuhua Gu, Xuecheng Wang, Qingyi Li
  • Publication number: 20140206650
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Inventors: Blaise S. Lippa, Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Chester A. Metcalf, III, Andrew J. Jackson
  • Publication number: 20140158116
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as asthma.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 12, 2014
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Jayhong A. Chong, Scott C. Coleman, Rory Curtis, Donato del Camino, Yu Gui Gu, Qingyi Li, Blaise S. Lippa, Chester A. Metcalf, III, Magdalene M. Moran, Michael D. Ryan, Dong Zou
  • Patent number: 8709819
    Abstract: A preparation method and its use of derivatization reagent for detecting L-carnitine or D-carnitine are provided. The present reagent is stable. It can be used for detecting L-carnitine or D-carnitine accurately and sensitively. That is to say, the reagent is applied to detecting the amount of synthesized or natural L-carnitine and the amount of mixing D-carnitine. The compound reagent is used for determining the chiral isomers of chemicals, biological reagents, health care reagents, cosmetic, body fluids and various foods, which contain L-carnitine or/and D-carnitine, and optical isomers of other chiral amino acids.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 29, 2014
    Inventors: Shuhua Gu, Qingyi Li, Xuecheng Wang
  • Publication number: 20110281293
    Abstract: A preparation method and its use of derivatisation reagent for detecting L-carnitine or D-carnitine are provided. The present reagent is stable. It can be used for detecting L-carnitine or D-carnitine accurately and sensitively. That is to say, the reagent is applied to detecting the amount of synthesized or natural L-carnitine and the amount of mixing D-carnitine. The compound reagent is used for determining the chiral isomers of chemicals, biological reagents, health care reagents, cosmetic, body fluids and various foods, which contain L-carnitine or/and D-carnitine, and optical isomers of other chiral amino acids.
    Type: Application
    Filed: October 9, 2009
    Publication date: November 17, 2011
    Inventors: Shuhua Gu, Qingyi Li, Xuecheng Wang
  • Publication number: 20110263897
    Abstract: The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production.
    Type: Application
    Filed: October 9, 2009
    Publication date: October 27, 2011
    Inventors: Shuhua Gu, Xuecheng Wang, Qingyi Li